Business Context and Reporting Period
Company: A.P. Pharma, Inc. (Note: Input metadata referenced "Heron Therapeutics," but the filing text identifies the registrant as A.P. Pharma, Inc.)
Reporting Period: Quarterly period ended September 30, 2008 (Form 10-Q).
Business Overview: A specialty pharmaceutical company developing controlled-release products using proprietary Biochronomer polymer technology. The company is focused on its lead candidate, APF530 (granisetron), for chemotherapy-induced nausea and vomiting (CINV), having completed a pivotal Phase III trial in Q2 2008. Other programs (APF112, APF580) have been temporarily deferred to conserve cash and focus on the APF530 New Drug Application (NDA) submission expected in December 2008.
Key Financial Metrics
| Metric (in thousands) | Q3 2008 | Q3 2007 | 9 Months 2008 | 9 Months 2007 |
|---|---|---|---|---|
| Contract Revenue | $64 | $121 | $348 | $280 |
| Operating Expenses | $6,341 | $5,357 | $19,962 | $16,097 |
| Net Loss | $(6,205) | $(4,685) | $(19,179) | $(12,462) |
| Net Loss Per Share (Basic/Diluted) | $(0.20) | $(0.15) | $(0.62) | $(0.80) |
| Cash and Cash Equivalents (End of Period) | $15,680 (Sep 30, 2008) $33,510 (Dec 31, 2007) | |||
| Marketable Securities | $859 (Sep 30, 2008) $1,552 (Dec 31, 2007) | |||
| Total Current Liabilities | $5,691 (Sep 30, 2008) | |||
| Accumulated Deficit | $(127,106) (Sep 30, 2008) |
Liquidity: The company reported a net cash outflow from operating activities of $18.2 million for the nine months ended September 30, 2008. Management believes existing cash, cash equivalents, and marketable securities ($16.5 million total) are sufficient to meet needs into the third quarter of 2009.
Material Changes vs. Prior Period
- Revenue: Contract revenue decreased 47% in Q3 2008 compared to Q3 2007 ($64k vs $121k) due to fluctuating activity levels from collaborators. For the nine-month period, revenue increased 24% ($348k vs $280k).
- Expenses: Operating expenses increased significantly. R&D expenses rose 10% in Q3 and 26% for the nine months, driven by higher payroll, stock-based compensation, and clinical trial costs for undisclosed pain products, partially offset by winding down APF530 Phase III costs. G&A expenses increased 67% in Q3 and 17% for the nine months, primarily due to professional fees and stock-based compensation.
- Interest Income: Net interest income dropped 80% in Q3 ($111k vs $561k) and 37% for the nine months ($547k vs $865k) due to lower average cash balances.
- Discontinued Operations: The company recorded a loss of $40k in Q3 and $120k for the nine months from discontinued operations (cosmeceutical business), compared to income in the prior year periods, due to adjustments for gross profit guarantees.
Outlook, Risks, and Unusual Items
- APF530 Status: Positive top-line data announced September 30, 2008. The 10mg dose met non-inferiority endpoints for three of four assessments. The company plans to submit an NDA to the FDA in December 2008.
- Cost Reductions: In November 2008 (subsequent event), the company implemented a corporate realignment, placing earlier-stage programs on hold and reducing headcount by approximately 35%. Expected severance costs are $0.3 million.
- Listing Risk: The company's stock is trading below $1.00 per share, violating Nasdaq continued listing requirements. While enforcement is suspended until January 16, 2009, failure to regain compliance could lead to delisting, adversely affecting liquidity and financing ability.
- Capital Needs: Future capital requirements depend on regulatory approval, commercialization partnerships, and litigation costs. The company may need to raise additional capital, which could be dilutive.
- Contingencies: The company has a gross profit guaranty liability related to a sold cosmeceutical business, with expected annual payments ranging from $100k to $200k.
Investor Verification Checklist
- NDA Submission: Verify the successful submission of the APF530 NDA to the FDA in December 2008 and the FDA's initial review timeline.
- Commercialization: Monitor progress on negotiations for a commercialization partnership for APF530, as the company is deferring other programs to focus on this.
- Nasdaq Compliance: Confirm whether the stock price recovers above $1.00 prior to the January 16, 2009 deadline to avoid delisting proceedings.
- Cash Runway: Validate the burn rate post-headcount reduction to ensure the projection of sufficiency into Q3 2009 remains accurate.
- Discontinued Operations: Review the final settlement or accrual adjustments regarding the gross profit guaranty for the sold cosmeceutical business.